Tyra Biosciences to Participate at September 2022 Investor Conferences

CARLSBAD, Calif.,Sept. 8, 2022/PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq:TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that management will participate at the following investor conferences:

Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. TYRA's proprietary in-house discovery platform, SNÅP, enables the rapid and precise refinement of structural design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies.  Leveraging SNÅP, TYRA is developing a pipeline of selective inhibitors of Fibroblast Growth Factor Receptors (FGFR), which are altered in approximately 7% of all cancers.  TYRA-300 is an FGFR3 selective inhibitor for oncology.  TYRA-200 is an FGFR2 inhibitor that TYRA is developing initially in intrahepatic cholangiocarcinoma. TYRA is also targeting achondroplasia and other FGFR3-related skeletal dysplasias and FGFR4 and REarranged during Transfection kinase (RET) related cancers. TYRA is based in Carlsbad, CA.  For more information about our science, pipeline and people, please visitwww.tyra.bioand engage with us onLinkedIn.